Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.51 |
| ▸ | MELK | Q14680 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31013179 | 1.00 | DYRK1A (0.51) | DYRK1AMELK | |
| SCHEMBL29725602 | 1.00 | DYRK1A (0.51) | DYRK1AMELK | |
| SCHEMBL27242937 | 0.87 | MELK (0.51) | DYRK1AMELK | |
| SCHEMBL27242945 | 0.83 | LRRK2 (0.57) | MELK | |
| SCHEMBL31013184 | 0.83 | LRRK2 (0.57) | MELK | |
| SCHEMBL29725390 | 0.82 | DYRK1A (0.49) | DYRK1AMELK | |
| SCHEMBL22964274 | 0.82 | DYRK1A (0.49) | DYRK1AMELK | |
| SCHEMBL27242948 | 0.81 | LRRK2 (0.46) | — | |
| SCHEMBL29725540 | 0.81 | LRRK2 (0.46) | — | |
| SCHEMBL22964272 | 0.81 | MELK (0.47) | DYRK1AMELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| CN-114174279-B | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-4010317-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20220281844-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114174279-A | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021026181-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | DYRK1A 1475/4885MELK 1357/4885 |
| US-20220281844-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | DYRK1A 1475/4885MELK 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.